Method of increasing the relative number of CD34.sup.+ cells in a cell population

• US 6,090,625 A
• Filed: 01/31/1996
• Issued: 07/18/2000
• Est. Priority Date: 02/02/1995
• Status: Expired due to Term

• Current Assignee: Ghazi Jaswinder Dhoot
• Original Assignee: Ghazi Jaswinder Dhoot
• Inventors: Abuljadayel, Ilham
• Primary Examiner(s): Wortman, Donna
• Assistant Examiner(s): Brumback, Brenda G.
• Application Number:
  US08/594,164
• Time in Patent Office: 1,630 Days
• Field of Search: 435/366, 435/372, 435/372.2, 435/372.3, 435/377, 424/93.1
• US Class Current: 435/372
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C12N 2501/06 Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
• CPC Class Codes: C12N 2501/50 Cell markers; Cell surface determinants
• CPC Class Codes: C12N 2506/11 from blood or immune system cells
• CPC Class Codes: C12N 5/0634 Cells from the blood or the immune system

Abstract

A method of increasing the relative number of CD34⁺ cells in a cell population is described. The method comprises contacting the cell population with an agent that causes the relative number of CD34⁺ cells to increase.

Claims

1. A method of increasing the relative number of CD34⁺ cells in a cell population including committed cells, which method comprises:

(i) contacting the cell population with an agent that operably engages said committed cells; and

(ii) incubating committed cells that are engaged by said agent such that the relative number of CD34⁺ cells increases as a result of said engaging.

2. The method of claim 1 wherein the committed cells are hemopoietic cell.

3. The method of claim 1 wherein the agent engages a receptor that mediates capture, recognition or presentation of an antigen at the surface of the committed cells.

4. The method according to claim 3 wherein the receptor is an MHC class I antigen or an MHC class II antigen.

5. A method according to claim 4 wherein said class I antigen is a Human-Leukocytc-Associated (HLA)-A receptor, an HLA-B receptor, an HLA-C receptor, an HLA-E receptor, an HLA-F receptor or an HLA-G receptor and said class II antigen is an HLA-DM receptor, an HLA-DP receptor, an HLA-DQ receptor or an HLA-DR receptor.

6. The method according to claim 5 wherein the receptor is an HLA-DR receptor.

7. The method according to claim 6 wherein the receptor comprises a β

-chain.

8. The method according to claim 7 wherein the β

-chain has homologous regions.

9. The method according to claim 8 wherein the receptor comprises at least the homologous region of the β

-chain of HLA-DR.

10. The method according to claim 9 wherein the agent is an antibody to the receptor.

11. A method according to claim 10 wherein the agent is a monoclonal antibody to the receptor.

12. A method according to claim 11 wherein the antibody is selected from the group consisting of monoclonal antibody CR3/43 and monoclonal antibody TAL 1B5.

13. The method according to claim 1 wherein said incubating is from 2 to 24 hours.

14. The method according to claim 1 wherein the committed cells are non-cancer cells.

15. The method according to claim 1 wherein the committed cells are differentiated cells.

16. The method according to claim 1 wherein the committed cells are selected from T-cell colony-forming cells (CFC-T cells), B-cell colony-forming cells (CFC-B cells), cosinophil colony-forming cells (CFC-Eosin cells), basophil colony-forming cells (CFC-Bas cells), granulocyte/monocyte colony-forming cells (CFC-GM cells), megakaryocyte colony-forming cells (CFC-MEG cells), erythrocyte burst-forming cells (BFC-E cells), erythrocyte colony-forming cells (CFC-E cells), T-cells and B cells.

17. The method according to claim 1 wherein the CD34⁺ cells are Major Histocompatibility Complex (MHC) class I⁺ and/or MHC class II⁺ cells.

18. A method according to claim 1 wherein the agent is used in conjunction with a biological response modifier.

19. A method according to claim 18 wherein the biological response modifier is an alkylating agent.

20. A method according to claim 19 wherein the alkylating agent is or comprises cyclophosphoamide.